Sexual functioning in females with depression in remission receiving escitalopram

Simple item page
dc.contributor.authorRoy, Pen_US
dc.contributor.authorGupta, Ben_US
dc.contributor.authorTripathi, Aen_US
dc.contributor.authorNischal, Aen_US
dc.contributor.authorDalal, PKen_US
dc.contributor.authorKar, SKen_US
dc.date.accessioned2020-04-10T01:44:55Z
dc.date.available2020-04-10T01:44:55Z
dc.date.issued2019-12
dc.description.abstractBackground & objectives: Sexual functioning is a strong determinant of quality of life. Sexual dysfunction has been widely reported due to depressive disorder as well as selective serotonin reuptake inhibitors. Thus, treatment with antidepressants can culminate in a double-edged sword, leading to drug discontinuation and symptom relapse. The objective of this study was to assess the sexual functioning of sexually active females with depression, currently in remission, receiving escitalopram and to compare with healthy controls. Methods: Fifty female patients with depression, currently in remission, with self-reported normal pre-morbid sexual function and receiving escitalopram for at least three months, were assessed on female sexual function index (FSFI) questionnaire and compared with healthy controls. Results: Half of the patients (n=25, 50%) in group A were found to have sexual dysfunction (FSFI score <26.55), while, 90 per cent (n=45) had decreased desire, 86 per cent (n=43) had decreased arousal, 54 per cent (n=27) had decreased lubrication, 68 per cent (n=34) had decreased orgasm, 62 per cent (n=31) had decreased satisfaction and 32 per cent (n=16) had pain during sexual activity. Patients receiving escitalopram had significantly higher sexual dysfunction as compared to healthy controls in mean total FSFI score (P < 0.001) and all mean domain scores of FSFI except pain. Interpretation & conclusions: A significant proportion of sexually active females with depression currently in remission, receiving escitalopram, reported dysfunction in all domains of sexual function; thus, routine screening for sexual dysfunction during follow up is advisable for early identification and prompt treatment.en_US
dc.identifier.affiliationsDepartment of Geriatric Mental Health, King George's Medical University, Lucknow, Uttar Pradesh, Indiaen_US
dc.identifier.affiliationsDepartment of Psychiatry, King George's Medical University, Lucknow, Uttar Pradesh, Indiaen_US
dc.identifier.citationRoy P, Gupta B, Tripathi A, Nischal A, Dalal PK, Kar SK. Sexual functioning in females with depression in remission receiving escitalopram. Indian Journal of Medical Research. 2019 Dec; 150(6): 606-611en_US
dc.identifier.issn0971-5916
dc.identifier.issn0975-9174
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/196082
dc.languageenen_US
dc.publisherIndian Council of Medical Researchen_US
dc.relation.issuenumber6en_US
dc.relation.volume150en_US
dc.source.urihttps://dx.doi.org/10.4103/ijmr.IJMR_1991_17en_US
dc.subjectDepressionen_US
dc.subjectescitalopramen_US
dc.subjectfemaleen_US
dc.subjectFSFIen_US
dc.subjectremissionen_US
dc.subjectsexual dysfunctionen_US
dc.titleSexual functioning in females with depression in remission receiving escitalopramen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijmr2019v150n6p606.pdf
Size:
427.54 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Medical Research